Akari Therapeutics Plc (AKTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
AKTX Stock Price Chart Interactive Chart >
AKTX Price/Volume Stats
| Current price | $0.25 | 52-week high | $1.61 |
| Prev. close | $0.26 | 52-week low | $0.22 |
| Day low | $0.24 | Volume | 108,500 |
| Day high | $0.27 | Avg. volume | 131,551 |
| 50-day MA | $0.40 | Dividend yield | N/A |
| 200-day MA | $0.69 | Market Cap | 18.65M |
Akari Therapeutics Plc (AKTX) Company Bio
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company is based in London, United Kingdom.
Latest AKTX News From Around the Web
Below are the latest news stories about AKARI THERAPEUTICS PLC that investors may wish to consider to help them evaluate AKTX as an investment opportunity.
Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem MeetingsNEW YORK and LONDON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the late-breaker presentation of a patient case study from the Phase 3 Part A clinical trial of nomacopan in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The case study, Clinical Response to Nomacopan in the Pediatric HSCT-TMA Setting, |
Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)Akari is targeting an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration in the first half of 2024Composition of matter patent application filed on long-acting PAS-nomacopan versions, which, if granted, provides patent protection until 2042Pre-clinical development on long-acting PAS-nomacopan has successfully produced multiple new and promising versions that are fully active, show high expression levels and have significantly enlarged hydrodynamic radi |
Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in AdultsBased on Type C guidance requested and received from the U.S. Food and Drug Administration (FDA), Akari announces it is moving forward into design and planning for pivotal Part B of the Phase 3 clinical trial of nomacopan for treatment of pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) in pediatric patients between 2 years and <18 years of ageAccording to FDA feedback, the PK/PD data from Part A of the clinical trial are consistent with predictions from |
Akari Therapeutics to Present at Biotech Showcase™ 2023NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET. The presentation will include progress highlights from Akari’s two priority pipeline programs: a Phase 3 clinical trial of nomacopan, a nove |
Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic ConferenceNEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will participate in the investor-focused Cantor Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference taking place in Miami December 7-8, 2022. Akari President and CEO Rachelle Jacques will take part in an ophthalmology panel on December 8 a |
AKTX Price Returns
| 1-mo | -28.31% |
| 3-mo | -44.44% |
| 6-mo | -54.46% |
| 1-year | -79.45% |
| 3-year | -83.66% |
| 5-year | -86.63% |
| YTD | -46.80% |
| 2022 | -68.67% |
| 2021 | -18.92% |
| 2020 | 5.71% |
| 2019 | 11.46% |
| 2018 | -63.74% |
Loading social stream, please wait...